EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated Analysis of scRNA-Seq and Bulk RNA-Seq Reveals Metabolic Reprogramming of Liver Cancer and Establishes a Prognostic Risk Model

Zhuang Xiong iD, Lizhi Li, Guoliang Wang, Lei Guo, Shangyi Luo, Xiangwen Liao, Jingfeng Liu, Wenhao Teng

Genes · 2024

DOI: 10.3390/genes15060755 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2024. Verfasst von Zhuang Xiong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreatobiliary Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China. Hauptthemen laut MEDLINE: Liver Neoplasms, Single-Cell Analysis, RNA-Seq. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Joint Funds for the Innovation of Science and Technology, Fujian Province, Funds of Natural Science Foundation of Fujian Province, high level talents training project of Fujian Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver cancer manifests as a profoundly heterogeneous malignancy, posing significant challenges in terms of both therapeutic intervention and prognostic evaluation. Given that the liver is the largest metabolic organ, a prognostic risk model grounded in single-cell transcriptome analysis and a metabolic perspective can facilitate precise prevention and treatment strategies for liver cancer. Hence, we identified 11 cell types in a scRNA-seq profile comprising 105,829 cells and found that the metabolic activity of malignant cells increased significantly. Subsequently, a prognostic risk model incorporating tumor heterogeneity, cell interactions, tumor cell metabolism, and differentially expressed genes was established based on eight genes; this model can accurately distinguish the survival outcomes of liver cancer patients and predict the response to immunotherapy. Analyzing the immune status and drug sensitivity of the high- and low-risk groups identified by the model revealed that the high-risk group had more active immune cell status and greater expression of immune checkpoints, indicating potential risks associated with liver cancer-targeted drugs. In summary, this study provides direct evidence for the stratification and precise treatment of liver cancer patients, and is an important step in establishing reliable predictors of treatment efficacy in liver cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsSingle-Cell AnalysisRNA-SeqHumansPrognosisGene Expression Regulation, NeoplasticTranscriptomeBiomarkers, TumorGene Expression ProfilingSingle-Cell Gene Expression AnalysisMetabolic Reprogramming

Stichwörter der Autor:innen

liver cancermetabolic reprogrammingprognostic risk modelsingle-cell RNA-seq

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Hepatopancreatobiliary Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
  • Interdisciplinary Institute for Medical Engineering, Fuzhou University, Fuzhou 350108, China.
  • Department of Pediatric Surgery, Shengli Clinical Medical College of Fujian Medical University, Fuzhou 350001, China.
  • CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences/China National Center for Bioinformation, Beijing 100101, China.

ORCID-Profile: Zhuang Xiong

Förderung

  • Joint Funds for the Innovation of Science and Technology, Fujian Province
  • Funds of Natural Science Foundation of Fujian Province
  • high level talents training project of Fujian Cancer Hospital
  • Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province, China
  • Joint Funds for the Innovation of Science and Technology, Fujian Province, China
  • National Natural Science Foundation of China

Zitieren

APA

Xiong, Z., Li, L., Wang, G., Guo, L., Luo, S., Liao, X., Liu, J., & Teng, W. (2024). Integrated Analysis of scRNA-Seq and Bulk RNA-Seq Reveals Metabolic Reprogramming of Liver Cancer and Establishes a Prognostic Risk Model. Genes. https://doi.org/10.3390/genes15060755

Vancouver

Xiong Z, Li L, Wang G, Guo L, Luo S, Liao X, et al. Integrated Analysis of scRNA-Seq and Bulk RNA-Seq Reveals Metabolic Reprogramming of Liver Cancer and Establishes a Prognostic Risk Model. Genes. 2024. doi:10.3390/genes15060755

BibTeX
@article{Xiong2024,
  author = {Xiong, Zhuang and Li, Lizhi and Wang, Guoliang and Guo, Lei and Luo, Shangyi and Liao, Xiangwen and Liu, Jingfeng and Teng, Wenhao},
  title = {Integrated Analysis of scRNA-Seq and Bulk RNA-Seq Reveals Metabolic Reprogramming of Liver Cancer and Establishes a Prognostic Risk Model},
  journal = {Genes},
  year = {2024},
  doi = {10.3390/genes15060755}
}
Kostenlos starten →